Lexaria’s Technology Lowers Blood Glucose More Effectively than Rybelsus-Branded GLP-1 drug Semaglutide Alone in Human Pilot Study
November 28, 2023
Consumer Packaged Goods
-
-
Lexaria’s Technology Improves the Oral Performance of the Rybelsus-Branded GLP-1 drug Semaglutide in Human Pilot Study
November 27, 2023
-
Blue Star Foods Provides Shareholder Update
November 27, 2023
-
Bit Origin Ltd Announces New Financing and Provides Business Plan Update
November 22, 2023
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Two New Canadian Patents Amid Continued Efforts to Safeguard the Applicability of Its DehydraTECH(TM) Technology in Multiple Jurisdictions and Sectors
October 26, 2023
-
Nightfood Schedules Investor Conference Call for Wednesday, November 1, 2023 at 4:30 PM Eastern
October 16, 2023
-
Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn
October 13, 2023
-
Lexaria Granted Two New Patents in Canada
October 12, 2023
-
Lexaria Announces Pricing of $1.6 Million Registered Direct Offering
September 29, 2023
-
Nightfood Holdings and Houdini Group Announce Exclusive License Agreement for Half-Baked Trademark
September 21, 2023
-
Lexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD
September 21, 2023
-
Inomin Drills 23% Magnesium and 0.19% Nickel over 179 Metres at Beaver South Confirming Large Deposit Potential
September 19, 2023
-
Blue Star Foods Repays Convertible Note
September 18, 2023
-
Nightfood Sleep-Friendly Snacks Coming Soon to Select BWH Hotels Properties in the U.S.
September 12, 2023
-
Better Choice Company Exploring Opportunities for its Bona Vida CBD Brand
September 12, 2023
-
Blue Star Foods Announces Pricing of $5 Million Public Offering
September 7, 2023